Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)
Eligible age
40–60 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.
Sponsor: Phynova Group Ltd
You may qualify if…
- ✓ Participants assigned female at birth (aged 40-60 years) will be recruited for the study.
- ✓ Females ages 40-60 who are weight stable and with a self- reported Body Mass Index (BMI) between 18.5 to 35 kg/m2.
- ✓ Willing to maintain their existing dietary and physical activity patterns throughout the study period.
- ✓ Have received a medical physical screening (annual physical) within the last 12 months where blood markers for diabetes were taken and results were within the healthy range.
- ✓ Self-reported \>40yrs in age and experiencing irregular periods.
- ✓ Willing and able to comply with the study protocol.
- ✓ Has given voluntary informed consent to participate in the study.
- ✓ Not currently using hormone replacement therapy (HRT) and/or \>3months since their last hormone treatment.
You may not qualify if…
- ✕ Participants assigned male at birth.
- ✕ Aged \> 60 or \< 40 years.
- ✕ Pregnant or lactating.
- ✕ Body mass index (BMI) \> 35kg/m2 or \< 18.5kg/m2
- ✕ Fasting blood glucose \>126mg/dL and/or HbA1c \>6.5% reported in routine medical physical screening within the last 12-months.
- ✕ Known history of diabetes mellitus (Type I/II) or the use of antihyperglycemic drugs or insulin to treat diabetes and related conditions.
- ✕ Currently using hormone replacement therapy (HRT) or had hormone therapy in the last 3 months.
- ✕ Postmenopausal, experiencing amenorrhea for \>12months.
Where it's recruiting
Los Angeles
Source: ClinicalTrials.gov · NCT07333885 · last updated 2026-01-12